Utility assessment is one of the most important stages of pharmacoeconomic analysis. Most of utility researches are conducted using standard gamble method which is considered the classic instrument of health state utilities assessment. This article presents a methodology of conducting researches using standard gamble. The problems and features of the interpretation of the results are covered, examples of research using props, as well as computer programs that calculate the values of the utility automatically are described.

Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as first-line therapy. Treatment with Tasigna compared with Gleevec characterizes as dominant or acceptable according to used time horizons.

Based on meta-analysis dates found, that the effectiveness of neuroprotective drugs and placebo are not differences or has not statistically significant relative placebo. The cost minimization analysis showed that only Cytoflavin and Tserakson, by reducing the time of hospital treatment, reduce the cost as compared to placebo at 22311 RUB and 21345 RUB, respectively. Cost effectiveness analysis, based on the clinical practice in Russia. It is shown, that when survival used as a criterion for effectiveness
evaluation, Cytoflavin with CER175003 RUB has the advantage.It was determined that the preferred scheme of treatment of acute ischemic drug is Cytoflavin therapy from the position direct costs reducing and have fewer CER while preserving the patient's life.

We present the results of the analysis of the monitoring of HIV / AIDS in the regions of the Central Federal District of Russia for the period 2009-2012. With the application of complex of economic and statistical methods were identified growth trends for all nine characteristics of the epidemiological situation in the context of regions. We have identified regions with negative trends in the development of indicators, which confirms the trouble problems. The methods of multidimensional groups on the
basis of regulation and regional analysis for evaluation of the situation in regions of the Central Federal district applied for the first time. Methodical approach to assessment of the situation analysis is recommended for the monitoring of the practical health care.

To solve the problem of infertility in the world assisted reproductive technologies (ART) are widely used, which relate to the financial and expensive high-tech medical care. This paper shows that the conduction of therapeutic correction of excessive thrombin generation and / or hypofibrinolysis in patients in a cycle of in vitro fertilization (IVF) is economically more justified than the standard management of patients by reducing recurrent IVF.

Based on a clinical study BCIRG 001 (Martin M., Mackey J., Pienkowski T.) and as an outcome of Markov simulation it was determined that the use of 6DAC for adjuvant therapy in 10 year horizon of research allows to increase the disease-free survival by 6,09%, and overall survival by 5,88% comparing to 6FAC. Use of 6DAC instead of 6FAC allows to reduce the number of patients with local relapse, regional relapse and metastasis insignificantly as well. In the result of direct costs analysis it was determined that for 10-years horizon cost rate for the treatment of one patient with breast cancer will be 1 198 300 RUB for 6DAC and 1 371 184 RUB for 6FAC. Direct and indirect costs rate of the breast cancer treatment were 1 683 844 RUB and 1 973 043RUB for the 6DAC and 6FAC schemes respectively. It was determined that the scheme of adjuvant therapy that includes Docetaxel besides of addition efficiency, allows to reduce the cost rate to 289 199 RUB in 10 years.

The range and sales analysis of pharmaceuticals for the dysmenorrhea treatment on the market of Russian Federation was carried out. Various groups of medicaments can be used for the dysmenorrhea therapy. Vast majority of medicines is prescribed and can not be used for self-treatment. The most commonly used medicines have quite extensive list of the registered therapeutic indications that complicates the analysis of sales whereas not only patients with dysmenorrhea provide the market requirements. Despite there is a broad assortment, just a few medicines lead in the sales market and have a stabile demand. Federal and local market structures of the dysmenorrhea treatment are slightly different (by the example of the Voronezh region). Pentalgine (in value) and Citramon (in volume) have the greatest sales among analgetics. Among antispasmodic the leader of sales is No-spa.